Life Science Invest Fund (LSIF) increases investment in Acarix

Acarix has announced a subscription rate of 96.2% for the TO3 warrant. Acarix will receive approximately SEK 22.6 million before issuance costs which we estimate will bring the company well into H2 2025. At LSIF we are pleased to see this strong support from the shareholders. LSIF is by far the largest subscriber in this round, and LSIF also participates in the guarantor consortium to secure an total subscription rate of 100%. For LSIF, this is our third financing round in Acarix emphazing our long term commitment to our portfolio companies.